Zemcelpro® Receives Positive CHMP Opinion for Blood Cancer Treatment
If approved, Zemcelpro® is anticipated to significantly increase access to donor-derived stem cell transplantation. This treatment could provide a potentially curative avenue for patients suffering from haematologic malignancies, such as leukemias and myelodysplastic syndromes. Notably, it would become the first and only therapy in the European Union to gain marketing authorization for adults requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning, especially for those without suitable donor cells.
What This Approval Means for Patients
This positive opinion from the CHMP of the European Medicines Agency (EMA) is a crucial step towards making Zemcelpro® available to those who desperately need it. The ExCellThera Inc. team has worked diligently to bring this innovative treatment to the forefront. An approval decision from the European Commission is expected in the near future, which will apply across all EU member states as well as certain neighboring countries.
The Components of Zemcelpro®
Zemcelpro®, also referred to as UM171 Cell Therapy, is a sophisticated product that relies on two components derived from the same cord blood unit – UM171-expanded CD34+ cells and unexpanded CD34- cells. This unique combination aims to optimize the outcomes of stem cell transplantation.
Urgent Need for Effective Treatments
Every year in Europe, more than 10,000 individuals are diagnosed with haematological malignancies that necessitate bone marrow transplants. Unfortunately, many of these patients face hurdles in accessing suitable donor cells, whether due to lack of appropriately matched donors or other medical barriers. The introduction of Zemcelpro® could address this significant gap in treatment options.
The favorable opinion from the CHMP was based on a comprehensive conditional Marketing Authorization Application (MAA) that highlights the potential of Zemcelpro® to mitigate some of the pressing issues in the healthcare landscape concerning hematology. Plans for additional filings with regulatory bodies in other regions, including the US and Canada, underline the broader intent to make this vital therapy accessible to as many individuals as possible.
Dr. Guy Sauvageau, CSO and Founder of ExCellThera, emphasized the importance of this development: "Every year, thousands are diagnosed with blood cancers and many do not have access to suitable donor-derived stem cells. Today’s positive opinion represents hope for these patients and their families."
CEO David Millette further added, "We take great pride in our commitment to bringing transformative cell therapy innovations to patients whose medical needs have not been addressed. With the momentum gathered today, we can bring Zemcelpro® to those who need it the most."
The safety profile of Zemcelpro® is in line with existing standards for allogeneic blood stem cell transplants following myeloablative conditioning, providing confidence in its administration once authorized.
About Zemcelpro®
Zemcelpro® is a cutting-edge cryopreserved haematopoietic stem cell transplantation product designed to improve treatment outcomes for people with blood cancers. Its development has involved rigorous clinical testing involving 120 patients in North America and Europe, to ensure its effectiveness and safety.
As a recognition of its potential, Zemcelpro® has received numerous designations, including orphan drug and regenerative medicine advanced therapy (RMAT) from regulatory agencies, accentuating its role in the therapeutic landscape for haematological conditions.
Future studies aim to further explore its efficacy among diverse patient populations, including pediatric cases and those with non-malignant haematological conditions.
Until official marketing authorization is granted, it is important to remember that the product remains subject to regulatory evaluations and is not yet available for treatment in its respective jurisdictions.
About ExCellThera and UM171 Technology
ExCellThera stands at the forefront of blood stem cell therapies, utilizing its proprietary Enhance™ platform. This technology promises to increase the viability of stem cells through enhanced expansion and counteracting culture-induced stress. The collaboration with biopharmaceutical companies aims to push the boundaries of cell and gene therapies, advancing healthcare for countless patients.
Frequently Asked Questions
What is Zemcelpro®?
Zemcelpro® is a novel therapy designed for patients requiring allogeneic haematopoietic stem cell transplants, particularly those lacking suitable donors.
What does the positive CHMP opinion mean?
The positive CHMP opinion is a critical approval step, recommending Zemcelpro® for conditional marketing authorization in the EU.
Why is this therapy significant?
This therapy could significantly improve treatment options for blood cancer patients lacking suitable donor cells, addressing a serious healthcare challenge.
What steps follow this opinion?
The European Commission will review the recommendation and make a final decision, which is expected soon.
Is Zemcelpro® currently available for use?
No, Zemcelpro® has not yet received full marketing approval and remains under regulatory review.
